New Research Published on Investigational Antimalarial Drug

WASHINGTON, May 17, 2017 /PRNewswire/ -- Animal neurotoxicity study findings for one of 60° Pharmaceuticals, LLC (60P) investigational agents have been accepted for publication in Travel Medicine and Infectious Disease, a peer-reviewed journal.

The journal article indicates that super-therapeutic doses of the investigational antimalarial agent tafenoquine (administered at levels greater than would be used in actual treatment) appear to be free of neurologic toxicity in adult rats.  Tafenoquine is an investigational antimalarial agent being evaluated for the prevention of malaria in adults. For the full article please go to: http://www.travelmedicinejournal.com/article/S1477-8939(17)30077-7/fulltext

The study, specifically designed to assess maximum tolerated dose and neurobehavioral effects of tafenoquine, measured clinical, blood, behavioral, motor activity and central nervous system changes after the drug was administered in rats at levels greater than expected to be used in actual treatment with humans.  No histopathological changes in the brain were found at doses up to the minimum lethal single dose in adult rats.

Malaria, a life-threatening disease caused by parasites that are transmitted to people through the bite of an infected mosquito, causes 429,000 fatalities and 212 million clinical cases annually¹. Travelers, employees of non-governmental organizations (NGOs) and military forces deployed to malaria-endemic countries are all at risk². 

"We are committed to improving the health and lives of people around the world through developing products that can help treat and prevent tropical diseases," said Dr. Geoffrey Dow, 60P CEO.

About 60P

60P, founded in 2010, focuses on discovering, developing and distributing new medicines for treatment and prevention of tropical diseases, including malaria and dengue.

60P's mission is supported through in-kind funding from the United States Department of Defense.  The company also collaborates with prominent research organizations in the U.S., Australia and Singapore.

60P is headquartered in Washington DC, with a subsidiary in Australia.

Further information is available on the company's website, www.60degreespharma.com. 

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.

The statements expressed herein are those of 60P and do not necessarily represent those of the United States Department of Defense or Department of the Army.

¹CDC. 2017. Malaria Facts. https://www.cdc.gov/malaria/about/facts.html

²WWARN. 2017. Antimalarial Drug Resistance. http://www.wwarn.org/about-us/malaria-drug-resistance

CONTACT:  Lois Kaufman, President 
Integrated Marketing Services
[email protected]
609-683-9055 x203

SOURCE 60 Degrees Pharmaceuticals, LLC